Kumaraguru Raja
Stock Analyst at Brookline Capital
(0.06)
# 4,312
Out of 4,918 analysts
15
Total ratings
15.38%
Success rate
-44.71%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kumaraguru Raja
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PALI Palisade Bio | Maintains: Buy | $16 | $1.01 | +1,484.16% | 2 | May 13, 2025 | |
| QNCX Quince Therapeutics | Initiates: Buy | $9 | $1.68 | +435.71% | 1 | Dec 18, 2024 | |
| SABS SAB Biotherapeutics | Initiates: Buy | $8 | $2.23 | +258.74% | 1 | Jun 7, 2024 | |
| FBRX Forte Biosciences | Initiates: Buy | $100 | $9.65 | +936.27% | 2 | May 30, 2024 | |
| OTLK Outlook Therapeutics | Downgrades: Hold | n/a | $1.93 | - | 1 | Aug 30, 2023 | |
| ADIL Adial Pharmaceuticals | Reiterates: Buy | $150 | $0.46 | +32,859.79% | 2 | Jul 11, 2023 | |
| GNTA Genenta Science | Assumes: Buy | $15 | $3.82 | +292.67% | 1 | Jun 29, 2023 | |
| RAIN Rain Enhancement Technologies Holdco | Reinstates: Buy | $21 | $3.80 | +452.63% | 1 | Jan 31, 2023 | |
| MNPR Monopar Therapeutics | Reinstates: Buy | $90 | $40.69 | +121.18% | 1 | Dec 9, 2022 | |
| VERU Veru Inc. | Maintains: Buy | $29 → $31 | $0.49 | +6,181.66% | 2 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $3,360 | $6.45 | +51,993.02% | 1 | Sep 21, 2021 |
Palisade Bio
May 13, 2025
Maintains: Buy
Price Target: $16
Current: $1.01
Upside: +1,484.16%
Quince Therapeutics
Dec 18, 2024
Initiates: Buy
Price Target: $9
Current: $1.68
Upside: +435.71%
SAB Biotherapeutics
Jun 7, 2024
Initiates: Buy
Price Target: $8
Current: $2.23
Upside: +258.74%
Forte Biosciences
May 30, 2024
Initiates: Buy
Price Target: $100
Current: $9.65
Upside: +936.27%
Outlook Therapeutics
Aug 30, 2023
Downgrades: Hold
Price Target: n/a
Current: $1.93
Upside: -
Adial Pharmaceuticals
Jul 11, 2023
Reiterates: Buy
Price Target: $150
Current: $0.46
Upside: +32,859.79%
Genenta Science
Jun 29, 2023
Assumes: Buy
Price Target: $15
Current: $3.82
Upside: +292.67%
Rain Enhancement Technologies Holdco
Jan 31, 2023
Reinstates: Buy
Price Target: $21
Current: $3.80
Upside: +452.63%
Monopar Therapeutics
Dec 9, 2022
Reinstates: Buy
Price Target: $90
Current: $40.69
Upside: +121.18%
Veru Inc.
May 18, 2022
Maintains: Buy
Price Target: $29 → $31
Current: $0.49
Upside: +6,181.66%
Sep 21, 2021
Initiates: Buy
Price Target: $3,360
Current: $6.45
Upside: +51,993.02%